Dr. Dorottya Nagy-Szakal is the Chief Medical Officer of Biotia, where she oversees clinical operations, medical affairs, laboratory leadership, and strategic communications with regulatory bodies including the FDA and CDC. She brings more than 15 years of experience in translational medicine and clinical microbiology, with deep expertise in clinical metagenomics for urine, joint fluid, and other challenging infections using next-generation sequencing technologies.

Before joining Biotia, Dr. Nagy-Szakal led clinical research on fecal microbiota transplantation, the gut-brain axis, multi-omics of complex disease, and COVID-19 diagnostics and therapeutics. She has authored more than 30 peer-reviewed articles in high-impact journals including JAMA, Nature Communications, Cell, mBio, and Scientific Reports, as well as multiple book chapters.

Dr. Nagy-Szakal earned her MD and PhD in clinical medicine from Semmelweis University of Medicine in Budapest, Hungary. She completed postdoctoral fellowships at Baylor College of Medicine / Texas Children's Hospital and Columbia University Medical Center. She currently serves as a research assistant professor at SUNY Downstate Health Sciences University.